{"id":30196,"date":"2025-03-24T18:31:12","date_gmt":"2025-03-24T10:31:12","guid":{"rendered":"https:\/\/flcube.com\/?p=30196"},"modified":"2025-03-24T18:31:13","modified_gmt":"2025-03-24T10:31:13","slug":"abbvie-sues-genmab-over-alleged-trade-secret-misappropriation-in-adc-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30196","title":{"rendered":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development"},"content":{"rendered":"\n<p>US pharmaceutical giant AbbVie (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (<a href=\"https:\/\/www.google.com\/finance\/quote\/GMAB:NASDAQ\">NASDAQ: GMAB<\/a>), Profound Bio US Co., ProfoundBio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie&#8217;s trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.<\/p>\n\n\n\n<p><strong>Details of the Allegations<\/strong><br>The dispute centers on Rina-S, a folate receptor alpha (FR\u03b1)-directed antibody drug conjugate (ADC) currently in Phase III study for ovarian cancer and other FR\u03b1-positive solid tumors. AbbVie claims that the defendants misappropriated its trade secrets to improve the hydrophilicity of drug-linkers in ADCs, a critical aspect of developing stable and effective conjugates. The lawsuit asserts that these trade secrets were improperly used in connection with Rina-S and other ProfoundBio ADC products.<\/p>\n\n\n\n<p><strong>Genmab&#8217;s Response<\/strong><br>Genmab, which acquired ProfoundBio&#8217;s product pipeline in May 2024, has firmly denied AbbVie\u2019s allegations. The company states it will vigorously defend against the claims, emphasizing that AbbVie has not asserted any patent rights against the defendants nor developed products containing the alleged trade secrets. Despite the ongoing litigation, Genmab notes that its collaboration with AbbVie related to epcoritamab will continue unaffected.<\/p>\n\n\n\n<p><strong>Implications and Ongoing Proceedings<\/strong><br>The lawsuit highlights the intense competition and high stakes in the development of ADCs, a promising area in oncology treatment. As the legal proceedings unfold, the case may set important precedents regarding the protection of trade secrets in biopharmaceutical research and development. Both companies will likely face scrutiny over their intellectual property practices and collaborative agreements in the biotechnology sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[234,35,368,851,853,735],"class_list":["post-30196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-legal-ip","tag-abbvie","tag-adc-xdc","tag-genmab","tag-nasdaq-gmab","tag-nyse-abbv","tag-profoundbio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie&#039;s trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30196\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie&#039;s trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30196\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T10:31:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T10:31:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development\",\"datePublished\":\"2025-03-24T10:31:12+00:00\",\"dateModified\":\"2025-03-24T10:31:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196\"},\"wordCount\":312,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2412-png.webp\",\"keywords\":[\"AbbVie\",\"ADC \\\/ XDC\",\"Genmab\",\"NASDAQ: GMAB\",\"NYSE: ABBV\",\"ProfoundBio\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30196#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30196\",\"name\":\"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2412-png.webp\",\"datePublished\":\"2025-03-24T10:31:12+00:00\",\"dateModified\":\"2025-03-24T10:31:13+00:00\",\"description\":\"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\\\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie's trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30196\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2412-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2412-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30196#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie's trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30196","og_locale":"en_US","og_type":"article","og_title":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development","og_description":"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie's trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.","og_url":"https:\/\/flcube.com\/?p=30196","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-24T10:31:12+00:00","article_modified_time":"2025-03-24T10:31:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30196#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30196"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development","datePublished":"2025-03-24T10:31:12+00:00","dateModified":"2025-03-24T10:31:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30196"},"wordCount":312,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30196#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","keywords":["AbbVie","ADC \/ XDC","Genmab","NASDAQ: GMAB","NYSE: ABBV","ProfoundBio"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30196#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30196","url":"https:\/\/flcube.com\/?p=30196","name":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30196#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30196#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","datePublished":"2025-03-24T10:31:12+00:00","dateModified":"2025-03-24T10:31:13+00:00","description":"US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A\/S (NASDAQ: GMAB), Profound Bio US Co., Profound Bio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie's trade secrets related to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ADC pipeline products of ProfoundBio. AbbVie is seeking both damages and broad injunctive reliefs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30196#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30196"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30196#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","width":1080,"height":608,"caption":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30196#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2412-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30196"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30196\/revisions"}],"predecessor-version":[{"id":30198,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30196\/revisions\/30198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30197"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}